News | October 27, 2025
Sanofi's Q3 profit dips marginally as Dupixent sales top €4 billion
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
The hospital opens with 300 operational beds, including 100+ ICU beds and 5 advanced operating theatres
Investment supports Company’s plans to manufacture the vast majority of advanced medicines in the U.S. to meet the needs of patients in the U.S.
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Subscribe To Our Newsletter & Stay Updated
